Sorafenib Inhibits the Imatinib-Resistant <i>KIT</i> <i>T670I</i> Gatekeeper Mutation in Gastrointestinal Stromal Tumor

Abstract

Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual molecular mechanisms of resistance. The Ba/F3 KIT(WK557-8del/T670I) cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KIT(V560del/V654A) and KIT(V559D/D820Y) mutant cells than dasatinib and sorafenib.